Regeneron Pharmaceuticals Inc. buy Benchmark Co.
Start price
07.07.26
/
50%
€582.60
Target price
07.07.27
€161.75
Performance (%)
12.14%
Price
16:53
€653.30
Summary
This prediction is currently active. The BUY prediction by Benchmark_Co_ currently has a performance of 12.14%. This prediction currently runs until 07.07.27. The prediction end date can be changed by Benchmark_Co_ at any time. Benchmark_Co_ has 50% into this predictionRegeneron Pharmaceuticals, Inc. is a biotechnology company that is engaged in the discovery, development, and commercialization of medicines for the treatment of serious medical conditions. The company's products include EYLEA, a treatment for wet age-related macular degeneration and diabetic macular edema; Dupixent, a treatment for atopic dermatitis and asthma; and Libtayo, a treatment for certain types of cancer. Regeneron also has a strong focus on research and development, with a pipeline of potential new treatments for a variety of diseases. The company is headquartered in Tarrytown, New York and trades on the NASDAQ stock exchange under the symbol REGN.
AI-generated
Performance without dividends (%)
| Name | 1w |
|---|---|
| Regeneron Pharmaceuticals Inc. | 12.389% |
| iShares Core DAX® | 2.334% |
| iShares Nasdaq 100 | 1.370% |
| iShares Nikkei 225® | 2.437% |
| iShares S&P 500 | 1.259% |
Comments by Benchmark_Co_ for this prediction
In the thread Regeneron Pharmaceuticals Inc. diskutieren
Regeneron Pharmaceuticals (REGN) was upgraded by Benchmark Co. from "hold" to "buy". They now have a $185.00 price target on the stock.
Ratings data for REGN provided by MarketBeat